Genomic Valley Biotech Intrinsic Value
GVBL Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹26.67 | ₹24.00 - ₹29.34 | -5.4% | Book Value/Share: ₹13.33, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹8.46 | ₹7.61 - ₹9.31 | -70.0% | Revenue/Share: ₹3.33, P/S: 2.0x |
Want to compare with current market value? Check GVBL share price latest .
Valuation Comparison Chart
GVBL Intrinsic Value Analysis
What is the intrinsic value of GVBL?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Genomic Valley Biotech (GVBL) is ₹26.67 (median value). With the current market price of ₹28.20, this represents a -5.4% variance from our estimated fair value.
The valuation range spans from ₹8.46 to ₹26.67, indicating ₹8.46 - ₹26.67.
Is GVBL undervalued or overvalued?
Based on our multi-method analysis, Genomic Valley Biotech (GVBL) appears to be trading near calculated value by approximately 5.4%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Operating Margin | 13.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.25x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
Related Pages for Genomic Valley Biotech
Additional stock information and data for GVBL
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-1 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-2 Cr | ₹-2 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹2 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |